Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

The development of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (CPI) treatment has been linked with improved tumor control in some cancer patients. The selection of treatments to inhibit irAEs must not impede antitumor immune responses. Pretreatment and/or on-treatment cytokine concentrations might help to predict cancer patients who are at risk of developing irAEs. Specific cytokines can be targeted to reduce...